Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients - Summary - MDSpire

Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients

  • By

  • Song Cheng

  • Dabin Chen

  • Rongrong Du

  • Chao Wang

  • Jiawen Xian

  • Liyuan Liu

  • Hong Wan

  • Ting Ye

  • May 26, 2026

  • 0 min

Share

Objective:

To develop and validate a nomogram model that integrates autoantibodies and systemic inflammation markers to predict the risk of bone metastases in patients with non-small cell lung cancer (NSCLC).

Key Findings:
  • DCA indicated that the nomogram provided a higher net benefit compared to 'treat-all' and 'treat-none' strategies across a range of threshold probabilities.
Interpretation:

Remove this section.

Limitations:
  • The study is retrospective, which may introduce bias.
  • The findings may not be generalizable to all NSCLC patient populations.
Conclusion:

Revise to reflect only the findings without implications.

Original Source(s)

Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients

  • by Song Cheng, Dabin Chen, Rongrong Du, Chao Wang, Jiawen Xian, Liyuan Liu, Hong Wan, Ting Ye

  • May 26, 2026

Related Content

Machine learning–based prediction of mortality in lung cancer: Application of severity-adjustment method

Editorial: The role of circular RNAs and MicroRNAs in non-small cell lung cancer: from mechanisms to therapeutic potential

Development of a CT-based comprehensive model with deep learning for differentiating pathological types of pulmonary ground-glass nodules